Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study).
Saved in:
| Title: | Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study). |
|---|---|
| Authors: | Bosio, Alberto1,2 (AUTHOR) alberto.bosio@iov.veneto.it, Cerretti, Giulia1,2 (AUTHOR), Padovan, Marta1,2 (AUTHOR), Del Bianco, Paola3 (AUTHOR), Polano, Maurizio4 (AUTHOR), Mandruzzato, Susanna1,5 (AUTHOR), Indraccolo, Stefano1,6 (AUTHOR), Manara, Renzo7,8 (AUTHOR), Librizzi, Giovanni7,9 (AUTHOR), Caccese, Mario2 (AUTHOR), Corrà, Martina2 (AUTHOR), Maccari, Marta1,2 (AUTHOR), Lonardi, Sara2 (AUTHOR), De Salvo, Gian Luca3 (AUTHOR), Lombardi, Giuseppe2 (AUTHOR) |
| Source: | Trials. 8/4/2025, Vol. 26 Issue 1, p1-10. 10p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 17456215 |
|---|---|
| DOI: | 10.1186/s13063-025-08997-2 |
